HbA1c Testing Market Size
| Study Period | 2018-2029 |
| Market Size (2024) | USD 1 Billion |
| Market Size (2029) | USD 1 Billion |
| CAGR (2024 - 2029) | 1.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
HbA1c Testing Market Analysis
The HbA1c Testing Market size is estimated at USD 1 billion in 2024, and is expected to reach USD 1 billion by 2029, growing at a CAGR of 1% during the forecast period (2024-2029).
People with diabetes mellitus had a greater risk of contracting COVID-19 infection. Various studies suggested that type-2 diabetes mellitus patients had increased chances of pulmonary damage following SARS-COV-2 infection. The hyperglycemic state was an important prognostic factor in diabetic patients exposed to SARS-CoV-2. HbA1c was the only predictor of COVID‐19 hospitalization among other chronic health conditions, and the risk for hospitalization increased at HbA1c ≥ 8%, which suggested its pathogenic importance and clinical utility. Therefore, the urgent need to control elevated blood glucose control gave a boost to the market during the pandemic.
HbA1c is measured to determine the three-month average blood sugar level and can be used as a diagnostic test for diabetes mellitus. It is also an assessment test for glycemic control in people with diabetes. The test is limited to a three-month average because the average lifespan of a red blood cell is four months. In diabetes, higher amounts of glycated hemoglobin indicate poorer control of blood glucose levels and have been associated with cardiovascular disease, nephropathy, neuropathy, and retinopathy.
The HbA1c Test is an accurate and easy-to-administer test and can be an effective tool in the diagnosis of diabetes. A combination of the Fasting glucose test and HbA1c test enhances the diagnostic accuracy of individual tests. The HbA1c test helps in glycemic control and predicts the lipid profile in diabetic patients. Due to increasing diabetes prevalence worldwide, the HbA1c test market is expected to continuously grow as part of the diagnostic and prognostic tool, leading to better patient care and clinical outcomes.
Furthermore, Government initiatives such as the roll-out of the world’s first program to transform diabetes care for people under 40 in August 2023 by NHS, in which around 140,000 people aged 18 to 39 years old will likely receive additional tailored health checks from healthcare staff, and support with diabetes management, such as blood sugar level control, weight management, and cardiovascular risk minimization are likely to facilitate the market growth over the forecast period. The NHS is the first health system in the world to put in place a national, targeted program for high-risk groups of people.
HbA1c Testing Market Trends
Rising Diabetes Prevalence is anticipated to boost the market studied
The diabetes population is expected to increase, registering a CAGR greater than 1.9% over the forecast period.
As per the International Diabetes Federation's latest estimates, about 10% of all diabetes cases are type-1, and the remaining are type-2; the adult diabetes population is approximately 537 million, and this number is going to increase by 643 million in 2030. The rate of newly diagnosed cases of diabetes is seen to increase, mainly due to obesity, unhealthy diet, and sedentary lifestyle. Diabetes can be detected using HbA1c tests, and an appropriate treatment regimen can be implemented. In 2022, the WHO Global Diabetes Compact outlined five diabetes targets to reach by 2030, focused on addressing metabolic risks, access to medication, and diagnosis. The outlook for a healthy future is further marked by sustained progress in strategies designed to remediate diabetes through control of calorie intake, physical activity, and medication.
The blood glucose data available from HbA1c is used in prescribing and monitoring medicines for diabetes and prediabetes, along with exercise and diet. The HbA1c is recommended to be performed at least twice a year in diabetes patients with stable blood glucose levels. The American Diabetes Association has recommended glycated hemoglobin as a possible substitute for fasting blood glucose for the diagnosis of diabetes.
HbA1c is an important indicator of long-term glycemic control as it provides a cumulative glycemic history of the preceding two to three months. Elevated HbA1c levels are a significant risk factor for coronary heart disease and stroke in people with or without diabetes. Furthermore, new product launches in the market are expected to facilitate the market over the forecast period. For instance, in May 2022, OmegaQuant launched an HbA1c blood sugar at-home testing kit, enabling users to test their hemoglobin A1c level to metabolize glucose. Typically, HbA1c testing requires a blood draw and lab analysis, but OmegaQuant’s HbA1c test allows for a simple finger stick so users can take the test on their own time and at their convenience, at home.
Owing to the rising diabetes prevalence, government initiatives and product launches in the market for HbA1c are expected to grow over the forecast period.
The Asia-Pacific region is Expected to Witness Highest Growth Rate Over the Forecast Period
The Asia-Pacific region is expected to grow, registering a CAGR of more than 4.5% in the market during the forecast period.
In Asia-Pacific, deaths attributable to high blood glucose due to type-2 diabetes increased among lower-middle and low-income Asia-Pacific countries and territories, and about half of them are undiagnosed and unaware of developing long-term complications. According to the International Diabetes Federation's latest estimates, 90 million adults in the age group of 20-79 are living with diabetes in the Southeast Asia Region, which is projected to increase to 113 million by 2030 and 152 million by 2045.
Countries like India and China have been recognized as potential developing markets due to the growing diabetic population in this region. These markets are associated with some challenges, like slow economic growth and increased competition. Effective strategies are needed to diagnose and manage patients with diabetic complications to reduce the healthcare resources and economic burden. According to the National Metabolic Disease Clinical Research Center, more hospitals in China will establish National Metabolic Management Centers (MMC) as part of their exploration of a new model of diabetes treatment.
Diabetes has been identified as a healthcare priority by the Ministry of Health, Labour, and Welfare in Japan. The high prevalence of type 2 diabetes is associated with a significant economic burden. Costs increase with an increasing number of complications. Well-organized medical insurance systems cover all medical fees for diabetes mellitus, and diabetics can visit doctors freely in Japan.
The region is witnessing a significant increase in the number of generic manufacturers, thereby giving a boost to the growth of the market studied.
HbA1c Testing Industry Overview
The HbA1c testing market is fragmented, with multiple players. Market leaders such as Abbott, Arkray, Roche, and Bio-Rad laboratories are focusing on product launches and technological collaboration to increase their foothold in the market. Furthermore, the players in the market are focussing on developing advanced HbA1c testing methods, point-of-care devices, lab-on-a-chip technologies, and non-invasive testing approaches. Such developments present opportunities for innovation and market growth.
HbA1c Testing Market Leaders
-
Abbott
-
Bio-Rad Laboratories, Inc.
-
F. Hoffmann-La Roche Ltd.
-
Arkray, Inc.
-
Beckman Coulter, Inc.
*Disclaimer: Major Players sorted in no particular order
HbA1c Testing Market News
- May 2023: The use of glycated hemoglobin (HbA1c) for diagnosis of diabetes mellitus has been accepted by Medicare for reimbursement in Australia.
- April 2023: FIND signed an agreement with Abbott, i-SENS Inc., and Siemens Healthineers to improve access to glycated hemoglobin (HbA1c) testing for diabetes diagnosis and management by offering a special price for point-of-care test kits for low and middle-income countries. The announcement follows an open call for partners issued by FIND in September 2021 and saw prices aligning closely to the minimal target ranges as stipulated in the target product profile for a point-of-care cardiometabolic device.
HbA1c Testing Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Drivers
- 4.3 Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Type
- 5.1.1 Handheld device
- 5.1.2 Benchtop device
-
5.2 End-User
- 5.2.1 Hospitals and Clinics
- 5.2.2 Diagnostic Laboratories
- 5.2.3 Other End-Users
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Rest of North America
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 Spain
- 5.3.2.3 Italy
- 5.3.2.4 France
- 5.3.2.5 United Kingdom
- 5.3.2.6 Russia
- 5.3.2.7 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 Japan
- 5.3.3.2 China
- 5.3.3.3 Australia
- 5.3.3.4 India
- 5.3.3.5 South Korea
- 5.3.3.6 Malaysia
- 5.3.3.7 Indonesia
- 5.3.3.8 Thailand
- 5.3.3.9 Philippines
- 5.3.3.10 Vietnam
- 5.3.3.11 Rest of Asia-Pacific
- 5.3.4 Latin America
- 5.3.4.1 Brazil
- 5.3.4.2 Mexico
- 5.3.4.3 Rest of Latin America
- 5.3.5 Middle East and Africa
- 5.3.5.1 South Africa
- 5.3.5.2 Saudi Arabia
- 5.3.5.3 Oman
- 5.3.5.4 Egypt
- 5.3.5.5 Iran
- 5.3.5.6 Rest of Middle East and Africa
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes population
- 6.2 Type-2 Diabetes population
7. COMPETITIVE LANDSCAPE
-
7.1 COMPANY PROFILES
- 7.1.1 Abbott
- 7.1.2 Bio-Rad Laboratories, Inc.
- 7.1.3 F. Hoffmann-La Roche Ltd.
- 7.1.4 Danaher Corporation
- 7.1.5 Siemens Healthcare GmBH
- 7.1.6 Thermo Fisher Scientific Inc.
- 7.1.7 Arkray, Inc.
- 7.1.8 Ortho Clinical Diagnostics
- 7.1.9 A.Menarini Diagnostics Ltd.
- 7.1.10 Beckman Coulter, Inc.
- *List Not Exhaustive
- 7.2 COMPANY SHARE ANALYSIS
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityHbA1c Testing Industry Segmentation
The HbA1c test is a blood test used to determine the average blood sugar level over two to three months. The HbA1c testing market is segmented by type (handheld device, benchtop device), by end-user (hospitals and clinics, diagnostic laboratories, other end-users), and by geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America).
The report offers the value (in USD) for the above segments.
| Type | Handheld device | |
| Benchtop device | ||
| End-User | Hospitals and Clinics | |
| Diagnostic Laboratories | ||
| Other End-Users | ||
| Geography | North America | United States |
| Canada | ||
| Rest of North America | ||
| Geography | Europe | Germany |
| Spain | ||
| Italy | ||
| France | ||
| United Kingdom | ||
| Russia | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | Japan |
| China | ||
| Australia | ||
| India | ||
| South Korea | ||
| Malaysia | ||
| Indonesia | ||
| Thailand | ||
| Philippines | ||
| Vietnam | ||
| Rest of Asia-Pacific | ||
| Geography | Latin America | Brazil |
| Mexico | ||
| Rest of Latin America | ||
| Geography | Middle East and Africa | South Africa |
| Saudi Arabia | ||
| Oman | ||
| Egypt | ||
| Iran | ||
| Rest of Middle East and Africa |
HbA1c Testing Market Research FAQs
How big is the HbA1c Testing Market?
The HbA1c Testing Market size is expected to reach USD 1 billion in 2024 and grow at a CAGR of 1% to reach USD 1 billion by 2029.
What is the current HbA1c Testing Market size?
In 2024, the HbA1c Testing Market size is expected to reach USD 1 billion.
Who are the key players in HbA1c Testing Market?
Abbott, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Arkray, Inc. and Beckman Coulter, Inc. are the major companies operating in the HbA1c Testing Market.
Which is the fastest growing region in HbA1c Testing Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2023-2029).
Which region has the biggest share in HbA1c Testing Market?
In 2023, the North America accounts for the largest market share in HbA1c Testing Market.
What years does this HbA1c Testing Market cover, and what was the market size in 2023?
In 2023, the HbA1c Testing Market size was estimated at USD 0.99 billion. The report covers the HbA1c Testing Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the HbA1c Testing Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
HbA1c Testing Industry Report
Statistics for the 2024 HbA1c Testing market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. HbA1c Testing analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
